Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
April 09 2024 - 4:05PM
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN),
a clinical-stage precision oncology company focused on the
discovery and development of next-generation small molecule kinase
inhibitors, today announced the appointment of Lori Kunkel, MD, to
its Board of Directors. Dr. Kunkel brings more than twenty-five
years of experience in oncology and immunology drug development and
commercialization to the Board.
“Lori has served as scientific advisor to
Enliven since its inception, and we are delighted to now welcome
her to our Board,” said Sam Kintz, MBA, Enliven’s Co-founder and
Chief Executive Officer. “She brings a wealth of experience as a
clinician, academic and industry executive, and we look forward to
her continued contributions and insights as we advance our two
parallel lead product candidates, ELVN-001 and ELVN-002, through
the next set of clinical milestones.”
Dr. Kunkel is an accomplished industry executive
and board member with a track record of success in corporate
strategy, clinical development and commercialization, and business
development. She currently serves on the Board of Directors of
Nurix Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and K36
Therapeutics, Inc. She is also a scientific advisor to several
clinical-stage oncology and immunotherapy companies. Previously,
Dr. Kunkel was the acting Chief Medical Officer (CMO) and board
member of Loxo Oncology, Inc. (acquired by Eli Lilly and Company).
She also served as the CMO at Pharmacyclics LLC (acquired by
AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals).
Prior to joining industry, Dr. Kunkel spent ten
years in academic medicine and served as a faculty member at the
Bone Marrow Transplant Unit in the Division of Hematology/Oncology
at the University of California, Los Angeles. She received her
medical degree from University of Southern California and her
bachelor’s degree in biology from University of California, San
Diego. She is board certified in internal medicine and held board
certifications in hematology and oncology.
“I am honored to transition from my role as a
scientific advisor to a member of the Board of Directors,” said Dr.
Kunkel. “I have been deeply engaged with the science at Enliven
since the beginning, and I am thrilled to now play a more direct
role in guiding its strategic direction. With the Company’s
upcoming announcement of initial proof-of-concept data from the
ongoing Phase 1a trial of ELVN-001, it is an exciting time for the
Company.”
About Enliven TherapeuticsEnliven Therapeutics
is a clinical-stage biopharmaceutical company focused on the
discovery and development of small molecule inhibitors to help
people with cancer not only live longer, but live better. Enliven
aims to address existing and emerging unmet needs with a precision
oncology approach that improves survival and enhances overall
well-being. Enliven’s discovery process combines deep insights in
clinically validated biological targets and differentiated
chemistry to design potentially first-in-class or best-in-class
therapies. Enliven is based in Boulder, Colorado.
Contact:
Investorsir@enliventherapeutics.com
Mediamedia@enliventherapeutics.com
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From Apr 2024 to May 2024
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From May 2023 to May 2024